Literature DB >> 19901127

Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer.

Michael Chao, Peter Gibbs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19901127     DOI： 10.1200/JCO.2009.25.6156

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  21 in total

1.  Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer.

Authors:  Zhen Yuan; Shuyuan Wang; Kemin Ni; Yixiang Zhan; Hong Ma; Xinyu Liu; Ran Xin; Xingyu Zhou; Zhaoce Liu; Xuanzhu Zhao; Xin Yin; Hangyu Ping; Yaohong Liu; Wanting Wang; Suying Yan; Qiurong Han; Wei Cui; Xipeng Zhang; Qinghuai Zhang; Chunze Zhang
Journal:  Med Sci Monit       Date:  2022-09-19

2.  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.

Authors:  Jeanne Tie; Yuxuan Wang; Cristian Tomasetti; Lu Li; Simeon Springer; Isaac Kinde; Natalie Silliman; Mark Tacey; Hui-Li Wong; Michael Christie; Suzanne Kosmider; Iain Skinner; Rachel Wong; Malcolm Steel; Ben Tran; Jayesh Desai; Ian Jones; Andrew Haydon; Theresa Hayes; Tim J Price; Robert L Strausberg; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs
Journal:  Sci Transl Med       Date:  2016-07-06       Impact factor: 17.956

3.  The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations.

Authors:  Rachel Wong; Jeanne Tie; Margaret Lee; Joshua Cohen; Yuxuan Wang; Lu Li; Stephen Ma; Michael Christie; Suzanne Kosmider; Cristian Tomasetti; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs
Journal:  Int J Cancer       Date:  2019-01-24       Impact factor: 7.396

4.  Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.

Authors:  Erin L Symonds; Susanne K Pedersen; Bernita Yeo; Hiba Al Naji; Susan E Byrne; Amitesh Roy; Graeme P Young
Journal:  Mol Oncol       Date:  2022-01-24       Impact factor: 7.449

Review 5.  Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.

Authors:  Maria F Arisi; Efrat Dotan; Sandra V Fernandez
Journal:  Int J Mol Sci       Date:  2022-04-18       Impact factor: 6.208

Review 6.  Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.

Authors:  M J Duffy; R Lamerz; C Haglund; A Nicolini; M Kalousová; L Holubec; C Sturgeon
Journal:  Int J Cancer       Date:  2013-08-27       Impact factor: 7.396

7.  Cell-free DNA copy number variations in plasma from colorectal cancer patients.

Authors:  Jian Li; Rachel L Dittmar; Shu Xia; Huijuan Zhang; Meijun Du; Chiang-Ching Huang; Brooke R Druliner; Lisa Boardman; Liang Wang
Journal:  Mol Oncol       Date:  2017-06-06       Impact factor: 6.603

8.  Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection.

Authors:  Erin L Symonds; Susanne K Pedersen; David H Murray; Maher Jedi; Susan E Byrne; Philippa Rabbitt; Rohan T Baker; Dawn Bastin; Graeme P Young
Journal:  Clin Epigenetics       Date:  2018-05-16       Impact factor: 6.551

Review 9.  Cell-Free DNA in Oncology: Gearing up for Clinic.

Authors:  Bryan C Ulrich; Cloud P Paweletz
Journal:  Ann Lab Med       Date:  2018-01       Impact factor: 3.464

10.  Monitoring colorectal cancer following surgery using plasma circulating tumor DNA.

Authors:  Xiao Sun; Tanxiao Huang; Fangsheng Cheng; Kaibing Huang; Ming Liu; Wan He; Mingwei Li; Xiaoni Zhang; Mingyan Xu; Shifu Chen; Ligang Xia
Journal:  Oncol Lett       Date:  2018-01-22       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.